• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Disulfiram is not effective as an adjunctive therapy to standard chemotherapy for glioblastoma

byDavy LauandAlex Chan
April 6, 2023
in Chronic Disease, Neurology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Adding disulfiram and copper to standard alkylating chemotherapy for glioblastoma (GB) was not associated with improved survival or quality of life, and was associated with increased adverse events.

Evidence Rating Level: 1 (Excellent)

New systemic treatments for glioblastoma (GB) have not been well-established since the arrival of temozolomide. However, disulfiram with or without copper has shown some benefit in preclinical studies for GB in vitro and in vivo. Therefore, this randomized controlled trial compared the effects of disulfiram and copper with standard alkylating chemotherapy to alkylating chemotherapy alone. This RCT spanned 7 centres in Norway and Sweden, including patients with first recurrence of histologically verified GB. Patients were randomized 1:1 to the control group, receiving the standard of care (SOC) alkylating chemotherapy treatment, or to the intervention group, receiving SOC plus disulfiram and copper. In total, there were 88 patients, with 45 randomized to SOC and 43 in SOC plus disulfiram and copper. The results demonstrated no difference in the primary outcome of 6-month survival post-randomization, with 62% survival in the control and 44% in the intervention (p = 0.10). There were also no significant differences at 9, 12, and 24 months respectively. Additionally, there was no difference in median progression-free survival (PFS), which was 2.6 (95% CI 2.4-4.6) months in the control and 2.3 (95% CI 1.7-2.6) months in the intervention. There was also no difference in the quality of life metric (EuroQol-5D-3L score) at 3 and 6 months, and no difference in mean daily growth from volumetric analysis from MRI. However, there were significantly greater adverse events in the intervention compared to control (41% vs 16%, p = 0.02) including events with CTCAE grade 3 or greater (34% vs 11%, p = 0.02). Overall, this study demonstrated no benefit to adding disulfiram and copper to standard alkylating chemotherapy treatment for GB, but demonstrated significantly more adverse events.

Click to read the study in JAMA Network Open

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Outcomes of Critically Ill Adult Patients With Acute Encephalitis

Early Blood Pressure Targets in Acute Spinal Cord Injury: A Randomized Clinical Trial

​​Perinatal Arterial Ischemic Stroke in Monochorionic Twins: A Retrospective Observational Single-Center Cohort Study

Tags: chemotherapyglioblastomaneurology
Previous Post

Double wide-area circumferential ablation not associated with improved freedom from recurrent atrial arrhythmias

Next Post

Apixaban may be safer than other options for long-term anticoagulation

RelatedReports

Brain lesions on MRI linked with subsequent increased stroke risk
Emergency

Outcomes of Critically Ill Adult Patients With Acute Encephalitis

September 25, 2025
Prevalence of hypertension among adolescents varies by race and BMI
Neurology

Early Blood Pressure Targets in Acute Spinal Cord Injury: A Randomized Clinical Trial

September 24, 2025
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Neurology

​​Perinatal Arterial Ischemic Stroke in Monochorionic Twins: A Retrospective Observational Single-Center Cohort Study

September 16, 2025
Patient Basics: Lung Cancer Overview
Oncology

Royalty financing deepens exposure to small cell lung cancer revenues

September 8, 2025
Next Post
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Apixaban may be safer than other options for long-term anticoagulation

Motivational interviewing and dietary counseling reduce BMI

Exercise improves arterial stiffness in children and adolescents

Video-based behavioral intervention benefits clinical skin examinations

Healthcare Barriers and Hidradenitis Suppurativa: The Patient Experience

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SOAP II Trial: Shaping Vasopressor Choice in Septic Shock
  • 2 Minute Medicine Rewind October 6, 2025
  • Factors in the Initial Resuscitation of Patients With Severe Trauma: The FiiRST-2 Randomized Clinical Trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.